Research and Development
PROTIER Biotech is leading the creation of new value through persistent innovation and intelligence.
We are driven by challenges and a passion for new drugs to develop patient-centered therapies. With the research capabilities and experience we have accumulated, we will introduce world-class therapies.
Targeted Protein Degradation (TPD)
Cells have proteolytic systems (ubiquitin-proteasome degradation system, lysosome-autophagy degradation system) that remove damaged or unnecessary proteins to maintain homeostasis. Targeted Protien Degradation (TPD) drugs are new modality drugs that utilize degradation systems to degrade disease-causing proteins. ProtierBiotech is focusing on the development of molecular glue degraders utilizing the ubiquitin-proteasome degradation system.
PROTIER-Glue Platform
Molecular glues are a completely revolutionary modality and therapy. Molecular glues enable the binding between proteins that normally don’t interact thereby degrading disease-causing proteins. Molecular glues can also degrade undruggable targets that cannot be treated with conventional small molecule compounds by introducing new protein-protein interactions. Compared to PROTAC, molecular glues are expected to have simpler structure, smaller molecular size, better pharmacological properties, higher membrane permeability, better cellular uptake and BBB penetration, and many advantages in CMC. PROTIER Biotech has developed the PROTIER-Glue platform to discover new neosubstrates and molecular glues.
ADC payload
We are developing Molecular Glue Degraders as payloads, one of the components of antibody-drug conjugates (ADCs). Molecular Glue Degraders are small molecule drugs that have more favorable pharmacokinetic profiles are easy to connect with linkers, can be effective even with low amount of drug. They are also suitable for manufacturing production due to their small molecular weight.
